Mettl3-Dnmt3b Axis Shapes CD8⁺ T Cell Differentiation and Anti-Tumor Immunity

Authors:

Abstract
The heterogeneity in patient responses to immune checkpoint blockade (ICB) therapy is largely attributed to the presence of distinct exhausted CD8⁺ T-cell subsets with differential therapeutic potentials. While progenitor exhausted (pTex) CD8⁺ T cells retain responsiveness to ICB, terminally exhausted (tTex) CD8⁺ T cells are highly refractory. However, the molecular mechanisms governing the divergent fate commitment of these subsets remain poorly understood. Here, we identify the RNA methyltransferase Mettl3 as a critical regulator of terminal differentiation in CD8⁺ T cells, functioning to suppress pTex cell generation. Across multiple murine tumor models, human samples, and adoptive transfer systems, Mettl3 expression was selectively enriched in tTex cells and inversely correlated with pTex populations. Mechanistically, Mettl3 promoted terminal exhaustion by stabilizing DNMT3B transcripts through m⁶A-dependent modification, thereby reinforcing CpG methylation and chromatin compaction at loci associated with memory and progenitor programs. This epitranscriptomic-epigenetic circuit restricted the proliferative burst capacity of T cells upon anti-PD1 therapy. Importantly, inhibition of the Mettl3-Dnmt3b axis reprogrammed chromatin accessibility toward a memory-like state, preserved progenitor potential, and enhanced effector function. Consequently, Mettl3-deficient T cells exhibited superior persistence, improved recall responses, and enhanced tumor control following anti-PD1 therapy. Collectively, our findings establish the Mettl3-Dnmt3b axis as a molecular rheostat controlling CD8⁺ T-cell fate decisions through coordinated epitranscriptomic and epigenetic regulation. This study identifies a therapeutically actionable mechanism underlying terminal T-cell dysfunction and highlights targeting the Mettl3-Dnmt3b pathway as a promising strategy to improve the durability and efficacy of ICB therapy.